Voting Rights

28 Feb 2008 11:06

Ardana PLC28 February 2008 Ardana plc VOTING RIGHTS AND CAPITAL Edinburgh, UK, February 28, 2008: Ardana plc (LSE:ARA), in conformity with theTransparency Directive's transitional provision 6, today notifies the market ofthe following: As at 28 February 2008, the issued share capital and voting rights of Ardana plcare as follows: Ardana plc's capital consists of 65,511,729 ordinary 1p shares with votingrights attached of one vote per ordinary share of which 12,681 ordinary sharesare held in Treasury. Therefore, the total number of voting rights in Ardana plc is 65,499,048. The above figure (65,499,048) may be used by shareholders as the denominator forthe calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, Ardana plc under the FSA'sDisclosure and Transparency Rules. For more information contact: Ardana plc Financial DynamicsDr. Huw Jones. Chief Executive Officer Julia PhillipsTel: + 44 (0) 131 226 8550 Emma Thompson Tel: +44 (0)20 7831 3113 Ardana plc (LSE: ARA) is an emerging pharmaceutical company focused on thediscovery, development and marketing of innovative products to improve humanreproductive health, a $25.5 billion market. Ardana's lead products are summarised below: • Teverelix LA, in development for three initial indications (prostate cancer, benign prostatic hyperplasia and endometriosis); • ARD-0705 a growth hormone secretagogue in Phase III for the diagnosis of growth hormone deficiency in adults; • Testosterone Cream, a transdermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase III trials; • Emselex(R), a once a day treatment for the symptoms of overactive bladder syndrome, which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis UK Limited; • StriantTM SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with confirmed hypogonadism; and • InvicorpTM, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe and has been launched in Denmark. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange